Why Your 2027 Part D Premium Jumped: The Federal Subsidy That Just Ended

If your Part D premium held roughly steady the last two years, that was not an accident, and it was not the market. It was a temporary federal program doing the work quietly in the background.

That program ends on December 31, 2026. CMS is concluding the Part D Premium Stabilization Demonstration and returning the standalone drug plan market to what it calls “traditional market conditions” for 2027. For a lot of Houston retirees, the first sign will be a number on the Annual Notice of Change that is larger than they expected.

This guide explains what the demonstration actually did, precisely what ends and what does not, the confirmed 2027 figures, who is shielded from the change, and what you can do about it between now and December 7.

The short answer: since 2025, a federal demonstration has been holding standalone Part D premiums down two ways — lowering the base premium everyone’s plan price is built on, and capping how much any single plan could raise its own premium year to year. CMS is ending it after 2026. The Inflation Reduction Act’s separate 6% cap on the base premium stays, so the base rises only from $38.99 to $41.33. But individual plans are no longer limited in what they can add on top. Compare your plan against the alternatives this Annual Enrollment Period rather than letting it renew.

What the demonstration actually did

The Inflation Reduction Act rebuilt the Part D benefit in 2025 — a hard out-of-pocket cap, no more coverage gap, and a much larger share of catastrophic costs moved onto plan sponsors. Good for beneficiaries. Destabilizing for the companies that had to price it.

CMS was concerned that standalone drug plans would respond with sharp, uneven premium increases, so it introduced the Part D Premium Stabilization Demonstration in 2025. It paid extra subsidies to standalone plan sponsors in exchange for restraint, and it worked on two levers at once:

Read the middle column and the right column as two different protections, because they are. The first made every plan’s starting point cheaper. The second put a ceiling on how far any one plan could move in a single year — which is the one most people actually felt.

CMS’s stated reason for ending it: plan sponsors “had sufficient experience under the redesigned Part D benefit to support their assumptions in developing prescription drug plan bids.” In plain terms, the training wheels were temporary and the agency judges the market ready.

What ends, and what stays

It is worth being precise here, because a lot of what you will read about this is vague.

So the consumer protections that matter most when you are actually sick — the out-of-pocket cap, the deductible ceiling, the ability to spread costs monthly — are all intact. What goes away is the cushion on the monthly premium itself.

The distinction that trips everyone up

You will see “the base beneficiary premium is capped at 6% a year” quoted as reassurance. It is true, and it is not the whole picture.

The base beneficiary premium is a national figure CMS calculates each year. It anchors the Part D late enrollment penalty and the income-related surcharge, and it feeds into what plans are paid. It rises from $38.99 in 2026 to $41.33 in 2027 — a 6.0% increase, right at the IRA ceiling.

Your plan’s premium is a different number. Each standalone drug plan submits its own bid. What you pay depends on that bid, and the 6% cap does not govern it. Through 2025 and 2026 the demonstration held the line on plan-level increases at $35 and then $50 a month. For 2027 there is no such limit.

That is the entire story in one sentence: the national anchor is still capped, and your individual plan is not.

There is a second consequence worth knowing. Because the base premium sets the Part D late enrollment penalty, a higher base means a higher penalty for anyone carrying one. The penalty is 1% of the base premium for each full month you went without creditable coverage, and it follows you for life. We cover how that is calculated in our guide to late enrollment penalties.

The confirmed 2027 numbers

Note what the out-of-pocket cap does. Once your spending on covered Part D drugs reaches $2,400 in 2027, you enter catastrophic coverage and pay nothing further for covered drugs for the rest of the calendar year. That is a $300 increase in the cap, and for anyone taking expensive specialty medication it remains the single most valuable feature of the redesigned benefit.

Two numbers we deliberately do not print here: the 2027 Part B premium and the 2027 income-related surcharge brackets. Those are announced in November and are not available as of this writing. When they land, they will affect what comes out of your Social Security check alongside this. Our IRMAA guide explains how the surcharge is calculated and how to appeal it after a drop in income.

Who is protected from this

Not everyone is exposed. Two groups are substantially insulated.

Extra Help / Low-Income Subsidy enrollees

If you qualify for the Part D Low-Income Subsidy — generally income below 150% of the federal poverty level with modest assets — you pay no premium at all in a benchmark plan, no deductible, and modest fixed copayments. Benchmark plans are the ones whose premiums fall at or below a regional threshold; nationally there were 88 of them in 2026, with between one and four available per state.

If you are in Extra Help, the thing to verify is not the premium — it is whether your plan is still a benchmark plan for 2027. When a plan’s premium rises above the threshold, enrollees can be reassigned or asked to pay the difference. That is the mechanism to watch. Our guide to Extra Help in Houston covers the income and asset tests.

People with full Medicaid and most dual eligibles

Full-benefit dual eligibles are automatically deemed eligible for Extra Help and are generally held harmless on premium in a benchmark plan. If you have both Medicare and Texas Medicaid, this news is largely not about you — though the plan reassignment question still applies. See our guide to dual eligibility in Harris County.

Everyone else — the large middle of Medicare beneficiaries who earn too much for Extra Help and buy a standalone drug plan on the open market — is exposed to whatever their plan decides to charge.

Does this hit Medicare Advantage plans too?

This is the question we get most, and the answer is genuinely different depending on how you get your drug coverage.

The demonstration was aimed at standalone prescription drug plans — the plans people buy alongside Original Medicare. Most Medicare Advantage plans include drug coverage bundled in, and those plans are financed differently. Medicare Advantage organizations receive rebate dollars they can apply to reduce what the member pays, which is why so many MA plans advertise a $0 or near-$0 premium.

Two cautions before anyone reads that table as a reason to switch to Medicare Advantage.

First, a $0 drug premium inside a Medicare Advantage plan is not free drug coverage. The deductible, the tiers, the pharmacy network and any prior authorization all still apply, and those are where the money actually moves for someone on expensive medication.

Second, moving from Original Medicare to a Medicare Advantage plan is a much larger decision than changing a drug plan. You take on a provider network and prior authorization, and — if you give up a Medigap policy to do it — you may not be able to get that policy back later, because Texas has no birthday rule and insurers may use medical underwriting outside a guaranteed issue right. We cover that in our guide to the Texas Medigap trap.

A drug plan premium is a reason to shop drug plans. It is rarely, on its own, a good reason to restructure your entire Medicare coverage.

Why premiums were rising underneath it anyway

It would be misleading to present this as a federal program ending and premiums jumping for no underlying reason. The demonstration was masking real cost pressure, not eliminating it.

KFF’s analysis makes the point directly: the subsidies “didn’t address broader cost pressures facing Part D plan sponsors associated with rising drug prices and increasing use of GLP-1s and expensive specialty drugs, which are likely to continue in 2027 and beyond.”

Three forces are pushing underneath:

• The benefit redesign shifted risk onto plans. The out-of-pocket cap means sponsors absorb catastrophic costs that used to be largely federal. That has to be priced somewhere.
• GLP-1 medications. Drugs like semaglutide and tirzepatide are widely prescribed, expensive, and taken indefinitely. We cover Medicare’s coverage rules in our GLP-1 guide.
• Specialty drug pricing generally. High-cost medications are a growing share of Part D spending.

The practical implication: this is unlikely to be a one-year adjustment that reverses. Treat the shopping habit you build this AEP as the one you will need every year.

Three Houston households, worked through

1. A 73-year-old on a low-premium plan with three generics

She pays a modest premium for a standalone plan and takes three generic medications, all on tier 1.

She is the most exposed and the least likely to notice in advance. Low-premium plans had the least room under the old caps and the most incentive to reprice once the caps came off. Because her drugs are cheap, the premium is her Part D cost — so a premium increase is close to a pure loss for her. She should compare on total annual cost, and for someone in her position a plan switch is usually straightforward: generics are widely covered, so the network and formulary risk of moving is low.

2. A 68-year-old taking one specialty medication

His monthly drug spend is high enough that he hits the out-of-pocket cap partway through the year.

For him, premium is the smaller question. What matters is whether his drug stays on the 2027 formulary, what tier it sits on, whether prior authorization or step therapy is added, and how quickly he reaches the $2,400 cap. A plan with a higher premium can easily be cheaper across the year if it treats his one expensive drug better. He should also look at the Medicare Prescription Payment Plan, which spreads out-of-pocket costs across the year rather than front-loading them in January.

3. A 70-year-old who qualifies for Extra Help and does not know it

Her income is modest and her savings are limited, but she has never applied.

She may be the biggest winner in this article. Extra Help would mean no premium in a benchmark plan, no deductible, and fixed low copays — which sidesteps the entire issue above. There is no penalty for applying and being turned down, and the asset limits are more generous than most people assume. She should also be checked for a Medicare Savings Program, which can pay her Part B premium; see our guide to Medicare Savings Programs in Texas.

What to do before December 7

1. Open the Annual Notice of Change. It arrived by September 30 and states your 2027 premium, deductible and tier changes in writing. Our ANOC decoder walks through it line by line.
2. Write down your drugs properly — name, strength, frequency — from the bottles rather than memory.
3. Compare on annual total, not premium. Premium plus deductible plus expected copays across twelve months is the only number that decides this.
4. Check your pharmacy. Preferred versus standard pharmacy status can move your costs more than a few dollars of premium.
5. Check each drug’s tier and restrictions for 2027, not 2026 — including prior authorization and step therapy.
6. Test your eligibility for Extra Help if your income is modest. It makes the rest of this moot.
7. If you are in Extra Help already, confirm your plan is still a benchmark plan for 2027.
8. Decide by December 7. After that, a standalone Part D plan generally cannot be changed until the next AEP unless a Special Enrollment Period applies.

One caution about the last point. The Medicare Advantage Open Enrollment Period from January 1 to March 31 is not a general Part D do-over — it is for people enrolled in a Medicare Advantage plan. If you have Original Medicare and a standalone drug plan, December 7 is your deadline.

Frequently asked questions

Talk it through with someone local

The useful response to this is not alarm, it is arithmetic. Some Houston households will find their plan barely moved. Others will find a number that makes switching obviously worth the afternoon it takes. The only way to know which you are is to run your own drug list against the 2027 plans — and that is a different exercise from reading a premium.

If your Annual Notice of Change has a figure on it you were not expecting, bring it in. Call 832-400-6538 or email sara@wisehealthins.com, or start with our Medicare page. We serve clients from North Houston and South Houston.

Wise Insurance Agency is an independent insurance agency licensed in Texas. We do not offer every plan available in your area. Any information we provide is limited to the plans we do offer in your area. Please contact Medicare.gov, 1-800-MEDICARE, or your local State Health Insurance Assistance Program for information on all of your options. This article is general information, not medical, legal or tax advice. Plan-specific 2027 premiums vary by plan and are published by CMS and the plans themselves; figures here are national parameters, not a quote.